Recently, it has been reported that morphine, a representative m-opioid receptor (MOR) agonist, showed an analgesic activity in the periphery in mice.
Recently, it has been reported that morphine, a representative m-opioid receptor (MOR) agonist, showed an analgesic activity in the periphery in mice. 1) Additionally it has been recognized that tolerance to the peripheral analgesia was not developed after the repeated administration of morphine in mice.
2) Furthermore, it has been reported that the MORs were increased around the inflammatory tissues in animals and humans. 3, 4) These reports indicate that the MOR agonists are useful analgesics in the periphery, especially against the inflammatory tissues.
On the other hand, there are nonsteroidal antiinflammatory drugs (NSAIDs) as peripheral analgesics but they do not have an analgesic efficacy toward some serious peripheral inflammations. 5 ) Therefore, we think that in the serious inflammation cases such as severe burns and grazes, MOR agonists can be effective medicines.
As MOR agonists not having the morphinane structures, fentanyl, 6) loperamide 7) and diphenoxylate 8, 9) are known. As for fentanyl, to improve the quality of life for cancer patients with pain, the plaster, 10) which has an analgesic activity that lasts for far seventy-two hours, has been developed so the patients do not need to go frequently to the hospital. Although loperamide and diphenoxylate are MOR agonists, they do not easily pass through the blood-brain barrier (BBB). Therefore, they are mainly used as antidiarrheals now.
Recently, it has also been reported that when loperamide was administered to a burn on a rat as a peripheral percutaneous cream, it was effective and could not easily pass through the BBB so the manifestation of tolerance did not occur. 11) Therefore, our final objective is the synthesis of MOR agonists having peripheral analgesic activity, and as the first step, we intended to synthesize compounds having more potent activities than loperamide in the two in vitro tests mentioned in the above summary. The three compounds mentioned above have a piperidine moiety in their structures. Currently there is no compound having a piperazine moiety in the structure as a MOR agonist on the market. Therefore, we started to synthesize compounds having a piperazine moiety in their structures. In this paper, we describe the synthesis of the compounds and their affinities to the human MOR and dand k-opioid receptors (DOR and KOR) expressed in CHO cells and their agonist activities on MOR in guinea-pig ileum.
Chemistry
To develop our new MOR agonists instead of the already known MOR agonists not having morphinane structures, we thought that our compounds had to have a structural feature. Therefore, based on the knowledge already known, we designed the piperazine (nϭ1) or homopiperazine (nϭ2) derivatives, which have side chains of fentanyl, diphenoxylate and loperamide on a nitrogen with another nitrogen directly connected to various aromatic rings including the heteroaromatic rings.
Considering the novelty of our compounds, we first selected the heteroaryl groups as aryl groups. It has been well known that a halogen located in the a-or g-position to the nitrogen in six-membered nitrogen heteroaromatic rings are so-called active halogens which easily react with amines. Therefore, we first synthesized the N-arylpiperazine or Narylhomopiperazine derivatives by the nucleophilic displacement reaction. As it is difficult to synthesize the N-aryl derivatives from the halides located in the inactive site (b-position) by this method, we synthesized them by the cross-coupling method 12, 13) using a palladium catalyst, a method that was recently developed by Buchwald. As a matter of course, this method is applicable to the synthesis of aromatic carbon ring derivatives represented by benzene. The synthesis by nucleophilic displacement reaction (Method A): When 2-chloropyrazine, 2-bromopyridine, 2-chloroquinoline, 2-bromothiazole, 4-bromopyridine and 4-chloroquinoline were heated with 1.5 equivalents of piperazine or homopiperazine at 169°C in 1,2,4-trimethylbenzene, mono-heteroaryl substituted piperazines and homopiperazines were selectively obtained in yields between 42% and 69%.
The synthesis of N-aryl derivatives using the palladium catalysts (Method B): When 3-bromopyridine, 5-bromopyrimidine, 4-bromoisoquinoline, iodobenzene, 1-bromonaphthalene and 2-bromonaphthalene were heated with piperazine or homopiperazine using 5% dichlorobis(tri-o-tolylphosphine)palladium (II) [PdCl 2 (P(o-tolyl) 2 ) 3 ] in the presence of NaO t Bu at 169°C in 1,2,4-trimethybenzene, the corresponding N-aryl derivatives were easily obtained as the target intermediates.
The phenolic derivatives 17A, 18A and 19A, except for the previously mentioned intermediates, were synthesized by demethylation using 48% hydrobromic acid from the com- mercially available methoxy derivatives 20A, 21A and 22A. Furthermore, in the other cases, the commercially available piperazine derivatives were used as the starting materials.
The N-arylpiperazines and N-arylhomopiperazines mentioned above were heated with 2-phenylethyl bromide, 3,3-diphenyl-3-cyanopropyl bromide or dimethyl (tetrahydro-3,3-diphenyl-2-furylidene) ammonium bromide 7) equivalent to 4-bromo-N,N-dimethyl-2,2-diphenylbutanamide in the presence of sodium carbonate in 1,3-dimethylbenzene or DMF to give the final target compounds.
Binding Assays and Agonist Activities
Each sample was transformed to the HCl salts to increase their solubility in water for the assays mentioned below and then converted into amorphous powder.
We selected the human MOR binding assay as the first screening. Next, to the some samples selected in this screening, we checked the human DOR and KOR binding assays to confirm the selectivity of the samples. And finally, we examined the potencies of the samples relative to that of [D-Ala 2 , N-MePhe 4 , Gly 5 -ol]-enkephalin (DAMGO), which is high selective MOR agonist in guinea-pig ileum. First, according to our policy as mentioned above, we synthesized 1Aa-c, fixed 2-pyridinylpiperazine, having a side chain of loperamide, diphenoxylate or fentanyl, and examined the affinity to the MOR. As the results, 1Aa having the side chain of loperamide showed the highest affinity to the receptor among them (Table 6) .
Next we examined the affinity of 1Aa to the DOR and KOR to confirm the selectivity of that (Table 7) . We confirmed that it had selectivity to the MOR because it showed extremely lower affinities to the DOR and KOR than to the MOR.
Furthermore, we confirmed the agonistic nature against MOR of 1Aa using naloxone, but it showed a lower potency when compared to DAMGO (Table 8) .
Although 2Aa and 3Aa had the 2-pyridinyl group of 1Aa replaced with the 3-pyridinyl or 4-pyridinyl group, 1Aa showed the highest affinity to the MOR among the tested compounds (Table 6) .
1Ba had the piperazine of 1Aa replaced by homopiperazine and it showed a lower affinity to the MOR than 1Aa (Table 6) .
Although several compounds (4Aa-10Aa) had the 2-pyridinyl group of 1Aa replaced with other heteroaryl groups except for the pyridines, nothing showed a higher affinity to the MOR than 1Aa (Table 6) .
Among the compounds having heteroaryl groups, the 2-pyridinyl derivative (1Aa) showed the highest affinity to the MOR. Therefore, we synthesized 11Aa having the 2- pyridinyl group of 1Aa replaced with a phenyl group and then examined its affinity. To our surprise, 11Aa showed a higher affinity to the MOR than 1Aa (Table 6) .
Next, we examined the affinity of 11Aa to the ODR and KOR to confirm its selectivity (Table 7) . We could then confirm that it had selectivity to the MOR because it showed extremely lower affinities to the DOR and KOR than to the MOR.
Furthermore, we confirmed the agonistic nature against MOR of 11Aa using naloxone but then it showed almost the same potency when compared to 1Aa so less than DAMGO (Table 8) .
Although 11Ba had the piperazine of 11Aa replaced with homopiperazine, 11B showed a lower affinity to the MOR than 11Aa (Table 6 ). This result was similar to the case of the 2-pyridine derivatives, therefore we could easily accept this result.
Among the 1-and 2-naphthyl derivatives (12Aa, 12Ba, 13Aa, 13Ba) having piperazine or homopiperazine, only 12Aa showed a higher affinity to the MOR than 11Aa (Table  6 ). Therefore, we checked the agonist activity against MOR of 12Aa, but it had a lower potency than 11Aa, so this compound was dropped.
Among the compounds (14Aa-27Aa) having the substituted phenyl groups, the 2-methoxyphenyl derivative 20Aa showed the highest affinity to the MOR among all our compounds (Table 6) .
We next examined the affinities of 20Aa to the DOR and KOR to confirm its selectivity (Table 7) . We confirmed that it had selectivity to the MOR because it showed extremely lower affinities to the DOR and KOR than to the MOR. Furthermore, we confirmed the agonistic nature against MOR of 20Aa using naloxone and then it finally showed a higher potency when compared to DAMGO and loperamide ( Table 8) .
The results mentioned above are summarized below: 1) The derivatives having a side chain of loperamide showed a high affinity to the MOR. 2) The piperazine derivatives showed a higher affinity to the MOR than the homopiperazine derivatives.
3) The derivatives having phenyl groups with substituent groups showed a high affinity to the MOR and a high agonist activity against MOR. 4) As the groups attached to the phenyl groups, both electron-donating groups and electron-withdrawing groups effectively increase the affinity. However, the ortho-substituted derivatives showed the highest affinity to the MOR, and in the order of metato para-substituted derivatives, the affinity decreased except for the two chlorine-substituted derivatives, 23Aa and 24Aa. 5) Finally, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the MOR and the highest potency on the MOR among our compounds.
As a result, we found 20Aa showing a higher affinity to the MOR and the higher agonist activity than loperamide as a reference. Therefore we are now examining why it has these strong activities and to optimize its structure.
Conclusion
Novel MOR agonists with piperazine and homopiperazine moieties in their structures were synthesized. It was found that 20Aa with the 2-methoxyphenyl moiety showed a higher The % inhibition of the stimulated muscle twitch produced by a compound was plotted against the log concentration of the compound to estimate the IC 50 (concentration of the compound to produce 50% inhibition of the twitch). The relative potencies of the test compounds were calculated by the following formula: Relative Potencyϭ DAMGO's IC 50 /Compound's IC 50 . The test compounds were confirmed to be an opioid agonist by antagonism of naloxone (sufficiently at 10 Ϫ8 M). Values are the meansϮ S.E.M. of n observations. affinity to the human MOR expressed on CHO-K1 cells than loperamide and a higher potency on MOR in guinea-pig ileum than loperamide. Therefore, after confirming that 20Aa has a peripheral analgesic activity in vivo, we will select 20Aa as the lead compound for the peripheral m-opioid analgesic mentioned above. Besides, we are now examining why it has these strong activities, and then optimize the structure of it followed by the pharmacological tests of the selected derivatives in vivo.
Experimental
Melting points were determined on a Yanaco micro melting point apparatus without correction. IR spectra were measured with a Nihon-bunko IR-810 spectrometer.
1 H-NMR spectra were recorded on a Varian Gemini 2000 spectrometer in CDCl 3 or dimethyl sulfoxide (DMSO)-d 6 using tetramethylsilane as the internal reference. The following abbreviations were used: sϭsinglet, dϭdoublet, ddϭdouble doublet, dtϭdouble triplet, tϭtriplet, qϭquartet, mϭmultiplet and brϭbroad. MS or high-resolution mass spectra (HR-MS) were obtained using JEOL JMS-DX303 or JEOL JMS-AX500 mass spectrometer. TLC was performed by using Silica gel 60F 254 (Merck). Column chromatography was performed with a Silica gel (BW-80S Fuji-sirial). Magnesium sulfate was employed as the drying agent. Dichlorobis(trio-tolylphosphine)palladium (II) and hydrogen chloride, 1.0 M solution in diethyl ether were obtained from Aldrich Chemical Company, Inc. The yields, physical and spectral data for the intermediates, 1B, 2-5A, 7-10A, 11B, 12A, B and 13A, B are shown in Tables 1 and 2 . The yields, physical and spectral data for the final products, 1Aa-c, 1Ba, 2-11Aa, 11Ba, 12Aa, 12Ba, 13Aa, 13Ba and 14-27Aa are shown in Tables 3 and 4 . The analytical data for the solid compounds among the above compounds, 6Aa, 7Aa and 22Aa, are shown in Table 5 .
1-Heteroarylpiperazine or -Homopiperazine (General Procedure A)-Method A A mixture of piperazine (646 mg, 7.50 mmol) or homopiperazine (759 mg, 7.50 mmol), heteroarylhalide (5.00 mmol) and 1,2.4-trimethylbenzene (20 ml) was stirred at 169°C for 8 h. The mixture was concentrated in vacuo and the residue was made alkaline with 1 N NaOH to pH 9 and extracted with CHCl 3 . The extract was dried, concentrated in vacuo to give a brown oil which was purified by column chromatography on silica gel. Elution with 7% MeOH in CHCl 3 gave the target molecule.
1-Arylpiperazine or -Homopiperazine (General Procedure B)-Method B A mixture of piperazine (610 mg, 7.08 mmol) or homopiperazine (709 mg, 7.08 mmol), aryl halide (5.02 mmol), sodium t-butoxide (680 mg, 7.08 mmol), dichlorobis(tri-o-tolylphosphine)palladium (II) (194 mg, 0.247 mmol) and 1,2,4-trimethylbenzene (20 ml) was stirred at 169°C for 24 h. After cooling, the mixture was diluted with THF and filtered through Celite ® . The filtrate was concentrated in vacuo to give a tan oil which was purified by column chromatography on silica gel. Elution with 7% MeOH in CHCl 3 gave the target molecule.
1-(Hydroxyphenyl)piperazine (17-19A) (General Procedure C) A mixture of 1-(methoxyphenyl)piperazine (1.00 g, 5.20 mmol) and 48% hydrobromic acid (15.0 ml, 278 mmol) was stirred at 140°C for 6 h. After cooling, the mixture was made alkaline with 3 N-NaOH to pH 9. The resulting precipitate was collected by filtration, washed with water, air-dried at room temperature to give 17-19A as an yellowish solid.
1-(2-Hydroxyphenyl)piperazine (17A): mp 118-120°C. Yield 54%. , 1.39 mmol) , sodium carbonate (500 mg, 4.72 mmol) and DMF (15 ml) was stirred at 100°C for 4 h. Then the mixture was concentrated in vacuo. After addition of water, the residure was extracted with CHCl 3 . The extract was dried and concentrated in vacuo to give a tan oil which was purified by column chromatography on silica gel. Elution with 3% MeOH in CHCl 3 gave the final target molecule.
2,2-Diphenyl-4-[4-(2-pyridinyl)piperazin-1-yl]butanenitrile (1Ab)
A mixture of 1-(2-pyridinyl)piperazine (240 mg, 1.47 mmol), 4-bromo-2,2-diphenylbutyronitrile (450 mg, 1.47 mmol), sodium carbonate (400 mg, 3.77 mmol) and 1,3-dimethylbenzene (15 ml) was stirred at 139°C for 24 h. The reaction mixture was concentrated in vacuo and after addition of water, the residue was extracted with CHCl 3 . The extract was washed with water, dried, and concentrated in vacuo to give a tan oil which was purified by column chromatography on silica gel. Elution with 2% MeOH in CHCl 3 gave 1Ab (213 mg, 38%) as yellowish viscous liquid.
1-(2-Phenylethyl)-4-(2-pyridinyl)piperazine (1Ac) A mixture of 1-(2-pyridinyl)piperazine (314 mg, 1.93 mmol), 2-phenylethyl bromide (400 mg, 2.16 mmol), sodium carbonate (400 mg, 3.77 mmol) and 1,3-dimethylbenzene (25 ml) was stirred at 139°C for 24 h. The reaction mixture was concentrated in vacuo. After addition of water, the residue was extracted with CHCl 3 . The extract was washed with water, dried, and concentrated in vacuo to give a tan oil which was purified by column chromatography on silica gel. Elution with 3% MeOH in CHCl 3 gave 1Ac (376 mg, 73%) as yellowish viscous liquid.
Preparation of HCl Salts (General Procedure E) A final compound (1.00 mmol) was dissolved in CHCl 3 (10 ml). 1.0 M Hydrogen chloride solution in diethyl ether (1.00 ml) was added into the solution, and the mixture was concentrated in vacuo. After addition of ethyl ether (15 ml) to the residue, the resulting solid was collected by filtration, washed with diethyl ether, air-dried at room temperature to give the HCl salts as a white amorphous powder.
Binding Assays to Human MORs Using [ 17) Male Hartley guinea-pigs weighing 300-500 g were used for this study. The myenteric plexus-longitudinal muscle strip of guinea-pig ileum was prepared as described by Rang (1964) .
Evaluation of MOR Agonist Activities in Vitro
18) The strip was suspended in a 4 ml organ bath, which contained Krebs solution (millimolar concentrations: NaCl 118; KCl 4.75; CaCl 2 2.54; KH 2 PO 4 1.19; MgSO 4 1.2; NaHCO 3 3.25; glucose 11) and 20 mM choline chloride, and was kept at 36°C and bubbled with 95% O 2 and 5% CO 2 . The resting tension of the myenteric plexus-longitudinal muscle strip was maintained at 250 mg. The intramural nerves were stimulated through two platinum electrodes with supramaximal rectangular pulses of 1.0 msec duration. The strip of guinea-pig ileum was stimulated at a frequency of 0.1 Hz. Compounds were added in 4-40 ml amounts and washed out with 4 ml portions of bath solution after their maximum effects had been noted. The % inhibition of the stimulated muscle twitch produced by a compound was plotted against the log concentration of the compound to estimate the IC 50 (concentration of the compound to produce 50% inhibition of the twitch). The relative potencies of the test compounds were calculated by the following formula: Relative PotencyϭDAMGO's IC 50 /Compound's IC 50 . The test compounds were confirmed to be an opioid agonist by antagonism of naloxone (sufficiently at 10 Ϫ8 M).
